Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Immuneering Corporation: Updates Inbound At The End Of The Month
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Analysts
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Oxford BioMedica (OTCMKTS:OXBDF) and Immuneering (NASDAQ:IMRX) Financial Contrast
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Immuneering to Present at the Leerink Global Healthcare Conference
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Immuneering (NASDAQ:IMRX) vs. GRI Bio (NASDAQ:GRI) Head-To-Head Survey
Insider Buying: Immuneering (NASDAQ:IMRX) Insider Buys $10,501.86 in Stock
Immuneering Corporation (NASDAQ:IMRX) Short Interest Update
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data
Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower
Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Rating of “Moderate Buy” from Analysts
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
Immuneering Corporation (NASDAQ:IMRX) Receives Average Rating of “Moderate Buy” from Analysts
Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High?
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
Immuneering Corporation - Special Call
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
Immuneering Announces Closing of $25 Million Private Placement
Immuneering Stock Rises 21.7% on Supply Agreement With LLY
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
Immuneering Announces $25 Million Private Placement
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib